arrow
B

Benjamin Greenberg

The University of Texas Southwestern Medical Center
H指数:59
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-in-human high dose AAV9 intrathecal gene therapy for paediatric CLN7 disease: a phase 1, open-label, single ascending dose, non-randomised clinical trial

首次人体高剂量AAV9鞘内基因治疗儿童CLN7病:一项1期、开放标签、单次递增剂量、非随机临床试验

2025-11-270
OAAI
Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study (vol 12, e200450, 2025)

Bennett JL,Fujihara K,Saiz A,Traboulsee AL,Greenberg BM,Weinshenker BG,等。来自SAkuraMoon开放标签扩展研究的视神经脊髓炎谱系障碍患者中萨他利珠单抗的长期疗效与安全性。Neurology® Neuroimmunology Neuroinflamm.(2025)12:e200450。doi:10.1212/NXI.0000000000200494。

2025-11-010
PRE
Delphi panel to understand the real-world occurrence and management of ofatumumab injection-related reactions among healthcare providers of people with relapsing multiple sclerosis

德尔菲法专家小组旨在了解在复发型多发性硬化症患者医疗保健提供者中,奥法木单抗注射相关反应的实际发生情况和管理措施。

2025-07-030
OA
Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data

视神经脊髓炎谱系障碍感染率分析:比较SAkuraMoon研究、上市后研究和基于美国医疗索赔数据的satralizumab治疗。

2025-07-010
PRE
Comparing new tools of artificial intelligence to the authentic intelligence of our global health students
2024-12-180
OAAI
AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient

针对50型遗传性痉挛性截瘫的AAV基因治疗:单例患者I期临床试验

2024-06-283
OA
Astrocytic stress response is induced by exposure to astrocyte-binding antibodies expressed by plasmablasts from pediatric patients with acute transverse myelitis
2024-06-240
OAAI
Gene-environment interactions: Epstein-Barr virus infection and risk of pediatric-onset multiple sclerosis
2024-02-091
OA